Abstract: A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.

Abstract: A tampon and delivery system for a pharmaceutical, holistic or medicinal component, includes: (1) a nonabsorbent vaginal implant having a generally cylindrical shape including a leading end and a cylindrical outer surface; (2) an outer delivery sheath applied to at least a portion of the cylindrical outer surface of the tampon, distal from the leading end (and preferably leaving the leading end exposed), where the outer delivery sheath comprises a formulation including (a) a water soluble polymer film carrier and (b) a pharmaceutical, holistic or medicinal component; and (3) an applicator containing the tampon and applied delivery sheath. Methods for preparation of the delivery system and methods of use are also disclosed.

Abstract: Surgical drapes reliably maintain sterility in the operating room and enable easy and efficient installation on and removal from a surgical instrument, such as a surgical instrument at the end of a robotic surgical arm. The surgical drape comprises a transitional sheath such that in a deployed configuration a second end of the sheath is spaced relatively away from a first end of the sheath, and in an un-deployed configuration the second end of the sheath is spaced relatively close to the first end of the sheath. The sheath may further include a stiffening member secured to the second end, a pull member coupled to the stiffening member, and at least one access port formed in the first end of the sheath, such that each access port is adapted for the passage of surgical instruments therethrough.

Abstract: A humidification system has a tube configured to transport gases. The tube is configured to be soaked prior to use and has a bead to hold liquid. Heat applied to the bead causes the liquid to be released as vapour. Gases flowing through the tube are heated and humidified by the vapour.

Abstract: A penile prosthetic includes an insertion tool contained inside of an inflatable bladder of a penile implant. The penile implant is sized for insertion into a dilated corpora cavernosum of a penis. The penile implant has a proximal tip that is insertable into the crus penis, with the inflatable bladder connected to the proximal tip. The inflatable bladder has a first column strength and includes a distal tip that is insertable into the glans penis. The insertion tool provides the inflatable bladder with an effective column strength that is greater than the first column strength.

Abstract: Organic compounds showing the ability to inhibit viral glycoprotein (GP)-mediated entry of a filovirus into a host cell are disclosed. The disclosed filovirus entry inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by filovirus including the type species Marburg virus (MARV) and Ebola virus (EBOV). Preferred inhibitors of the invention provide therapeutic agents for combating the Ivory Coast, Sudan, Zaire, Bundibugyo, and Reston Ebola virus strains.

Abstract: Provided herein are compositions for applying a reference marker pattern or grid to the surface of an object to be imaged three-dimensionally. These compositions can be quick drying for ease of use. Methods of use of the compositions are also provided as well as devices and kits for the application of the compositions.

Abstract: The invention relates to medicine and pharmacology, more particularly to a pharmaceutical composition in the form of vaginal suppositories for treating candidal vaginitis and vulvovaginitis, containing antimycotics and prebiotics. The contents of the composition for therapeutic use make it possible to achieve the synergistic effect of stimulating the growth of the normal vaginal microflora through the presence of prebiotics and inhibiting the growth and eliminating pathogenic Candida fungi through the presence of modern antimycotics. Furthermore, the composition substantially contains such antimycotics to which representatives of the normal flora, i.e. lactobacilli and bifidobacteria, are insensitive. The method for treating mycetogenous or bacterial vaginosis, vaginitis and vulvovaginitis is carried out with the aid of the antimycotic and prebiotic pharmaceutical composition in a medicinal form for local application.

Abstract: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.

Abstract: Test methods for assessing irritation of portions of skin are provided. The method may include irritating a portion of skin by contacting the portion of skin with a chemical irritant; irritating the portion of skin by physical irritation; and assessing erythema or dryness of the portion of skin after irritating the steps. Alternatively, the method may include irritating a portion of skin with a chemical irritant; irritating the portion of skin by physical irritation; treating the irritated portion of skin by wiping the irritated portion of skin with a test sample; and assessing erythema or dryness of the portion of skin after the wiping step. A method of irritating a portion of skin to assess one of erythema and dryness may include irritating a portion of skin with a chemical irritant and irritating the portion of skin by physical irritation.

Abstract: Controlled release melatonin formulations are useful for imparting avoidance of mood depression which may be associated with administration of melatonin in conventional form comprising. Particular embodiments of methods use formulations designed to release melatonin according to a profile that simulates a normal endogenous melatonin nocturnal profile. The methods also include co-administration with additional medicaments.

Abstract: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.

Abstract: A method, medicated feminine sanitary products and compositions for reducing menstrual blood loss in a female are provided. The method comprises delivering an active agent to the uterine cavity by administering intravaginally to the female a therapeutically effective amount of the active agent on a medicated feminine sanitary product during menstrual bleeding, wherein the medicated feminine sanitary product is routinely utilized to absorb the menstrual flow, wherein the active agent is incorporated in the medicated feminine sanitary product as a pharmaceutically acceptable composition, the active agent is any of an antifibrinolytic and a hemostatic agent.

Abstract: Articles comprising one or more calcium salts are provided. The articles can contain one or more calcium salts in an amount effective to reduce the production of TSST-1 by at least about 50% when measured by the Shake Flask Method. In certain embodiments, the one or more calcium salts can be substantially non-lethal to Staphylococcus aureus when measured by the Shake Flask Method, and/or to Lactobacillus crispatus, Lactobacillus gasseri, and/or Lactobacillus iners when measured by the Maximum Tolerated Dose Test.

Abstract: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.

Abstract: This invention provides a spermicidally and virucidally effective, vaginally applicable formulation, having the following approximate composition of essential ingredients: at least one benzalkonium chloride, in an amount from 0.05 to 0-0.2%; at least one spermicide selected from the group consisting of nonoxynols in an amount of from 0.05-12%, octoxynol-9 in an amount of from 0.05-4%, and triclosan in an amount from 0.05-2%; a biologically acceptable emollient, in an amount from 1-5%; hydroxypropyimethyl cellulose, in an amount from 0.1-3%; sodium carbomer, in an amount from 0.1-1%; de-ionized water, making up the balance. The composition has the attributes of (a) a semi-solid, essentially clear gel consistency and appearance, and (b) the ability to maintain a presence in the human vagina in the presence of mucous secretions therein, in virucidally effective amounts, for at least 24 hours after application thereto.

Abstract: A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of fibers or non-woven fabrics made of a safe polymer material incorporating a medication that is released by dissolution of the fibers or non-woven fabrics over time, and more particularly a treatment method for controlling or regulating the pH in the vagina by stabilizing and adjusting the pH in the vagina by minimizing the impact of the vaginal flora.

Abstract: An applicator having an enhanced grip portion. The applicator can include a barrel portion having an insertion end, a withdrawal end, and a barrel exterior surface, the barrel exterior surface being a barrel color, a grip portion positioned opposite the insertion end having a grip exterior surface, and a plunger having a plunger exterior surface. The applicator can further include gripping indicia disposed substantially on the grip exterior surface. The gripping indicia can include visual indicia and/or tactile indicia.

Abstract: An odor-controlling bodily fluid absorbent member comprises (a) an absorbent material or substrate; and (b) a halo active aromatic sulfonamide compound of Formula (I): wherein R1, R2, R3, R4, R5, X, M, and n are as described herein; and wherein at least one of R1, R2, R3, R4, and R5 is not hydrogen. The absorbent member effectively controls odor arising from various body fluids.

Abstract: A method is provided for manufacturing a medicated tampon assembly having a tampon body, the method including applying a formulation including a therapeutic agent to a substrate to produce a plurality of dosage forms; separating one of the dosage forms from the substrate; and coupling one of the dosage forms to the tampon body. A medicated tampon assembly is provided including a dosage form including a formulation including a therapeutic agent; a substrate portion separated from a substrate, wherein the substrate portion is coupled to the dosage form; and a tampon body having a distal end, wherein the substrate portion is coupled to the distal end of the tampon body.

Abstract: Drug delivery compositions which are suitable for vaginal administration for the treatment of diseases and disorders in the urogenital tract are described. The compositions may be in the form of a tablet, liquid suspension or dispersion, dried powder, topical ointment, cream, foam, suppository, or aerosol. The drug delivery compositions are administered directly to the vagina and do not require the use of a solid device. This method of administration reduces the systematic levels of the drugs.

Abstract: A method of capturing bodily fluid in a mammalian body includes inserting the fluid management device into the mammalian body and transporting bodily fluid. The bodily fluid is transferred via at least one fluid transport element that is capable of interfacing with a mammalian body element to provide a substantially uninterrupted fluid conduit. The fluid conduit provides a fluid path between at least one fluid transport element and the storage element. A distal portion of the at least one fluid transport element is capable of extending away from the fluid storage element.

Abstract: A personal-care article, for receiving body exudates, having a self-assembling peptide is provided.

Abstract: Provided are articles containing a solid surface material with an antimicrobial agent in a thermoset and/or thermoplastic resin matrix, wherein the antimicrobial agent comprises a chitosan-metal complex.

Abstract: An applicator having an enhanced grip portion. The applicator can include a barrel portion having an insertion end, a withdrawal end, and a barrel exterior surface, the barrel exterior surface being a barrel color, a grip portion positioned opposite the insertion end having a grip exterior surface, and a plunger having a plunger exterior surface. The applicator can further include gripping indicia disposed substantially on the grip exterior surface. The gripping indicia can include visual indicia and/or tactile indicia.

Abstract: The invention relates to a therapeutic device for the delivery of therapeutic agents, e.g. a peptide such as leuprolide, via the vagina to a female mammal. In some embodiments, the invention also relates to methods for the treatment of obesity and eating disorders, diabetes, multiple sclerosis (MS), endometriosis, uterine fibroids, polycystic ovarian disease, various cancers such as breast cancer, acne, hirsutism, microbial or fungal or viral infections such as bacterial vaginosis or AIDS/HIV, and chronic diseases using a disclosed vaginal device.

Abstract: A method is provided for manufacturing a medicated tampon assembly having a tampon body, the method including applying a formulation including a therapeutic agent to a substrate to produce a plurality of dosage forms; separating one of the dosage forms from the substrate; and coupling one of the dosage forms to the tampon body. A medicated tampon assembly is provided including a dosage form including a formulation including a therapeutic agent; a substrate portion separated from a substrate, wherein the substrate portion is coupled to the dosage form; and a tampon body having a distal end, wherein the substrate portion is coupled to the distal end of the tampon body.

Abstract: A method of inhibiting double-stranded DNA virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors. In another embodiment, the method involves administering an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors to a susceptible tissue or cell.

Abstract: A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell.

Abstract: A personal-care article, for receiving body exudates, having a self-assembling peptide is provided.

Abstract: A hygiene article having calcium sugar phosphate is provided. The calcium sugar phosphate reduces the production of Toxic Shock Syndrome Toxin-1 (TSST-1) by Staphylococcus aureus.

Abstract: A hygiene article having calcium sugar acid salt is provided. The calcium sugar acid salt reduces the production of Toxic Shock Syndrome Toxin-1 (TSST-1) by S. aureus.

Abstract: The present invention is directed to an implantable device comprising a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents. The invention is further directed to methods of using and the process of preparing, the implantable device.

Abstract: In a tampon device (100) for insertion into the vulva, with a packing (110) of absorbent substance for taking up menstrual fluid, problems associated with menstruation, such as painful muscle tension and cramps in the area of the vulvar musculature, are alleviated or eliminated by the fact that a magnetic substance (120) interacting with the earth's magnetic field is integrated into the packing (110).

Abstract: The application of active ingredients, exemplified by GML, to absorbent fibers, such as rayon fibers, used in tampon manufacture at very low levels has been found to maintain efficacy in the inhibition of the production of toxic shock syndrome toxin one (TSST-1) produced by S. aureus without overtly killing the microorganism to achieve the desired reduction while avoiding undesired test results that suggest the presence of “impurities” in some jurisdictions.

Abstract: Non-absorbent articles containing an additive are disclosed. The non-absorbent articles include an effective amount of an inhibitory compound such as cerulenin, triclosan, or hexachloroprene, for example, to substantially inhibit the production of TSST-1 by Gram positive bacteria.

Abstract: A vaginal care composition is introduced directly into the vagina in the form of an ovule, a cream or an ointment or with a tampon or which is brought into a position outside the vagina on a panty liner. The composition comprises viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures, saccharide(s), vitamin A, and zinc.

Abstract: An applicator for introducing a therapeutic substance into a body cavity of a subject in need of the therapeutic substance is provided. The applicator has the look and feel of a conventional tampon applicator but delivers a therapeutic substance. Generally, the applicator has a first outer member having a shape suitable for insertion into a body cavity of a mammal and has a dispensing end and a second end distal to the dispensing end. A second inner member is coaxially and slidably housed within the first member such that one end of the second inner member is within the first member. The applicator of the present invention also has at least one aperture located in a side wall of the outer member. The aperture is located on the side wall of the outer member between the dispensing end and the second end of the outer member.

Abstract: A method of joining and/or scaling tissues in a surgical procedure or medical treatment, comprising the steps of: (1) applying a matrix protein, a photoactivatable metal-ligand complex and an electron acceptor to a tissue portion; (2) irradiating said tissue portion to photactivate the photoactivatable metal-ligand complex: thereby initiating a cross-linking reaction of the matrix protein to seal said tissue portion or join said tissue portion to an adjacent tissue portion.

Abstract: pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water; and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous media. The films demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, extrusion process, or other process that maintains the required uniformity of the film.

Abstract: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.

Abstract: The invention relates to absorbent, cross-linked polymers based on partially neutralized, monoethylenically unsaturated monomers that bear acidic groups. Said polymers exhibit improved properties with regard to their ability to transport liquids in a swollen state. The surface of the polymers is postreticulated, using a combination of an organic cross-linking compound, excluding polyols, and a cation that is in salt form in an aqueous solution.

Abstract: Compositions including an isolated Bacillus species, spores or an extracellular product of B. coagulans, suitable for topical application, for inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus are disclosed. Methods of inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus by topical application of compositions that include an isolated Bacillus species, spores or an extracellular product of a B. coagulans strain are disclosed.

Abstract: The invention provides an exotoxin inhibitory factor, compositions containing the factor, methods of using the compositions.

Abstract: Compositions having synergistic effective amounts of one or more antibacterial agents, a nitroimidazole, and/or a sulfonamide or a molecule or compound having folic acid antagonist effect and nitroimidazole substitution in addition, with or without an antifungal agent effective against a Candida species. The compositions are particularly useful in the treatment of genitourinary infections and their extragenital complications. Vaccination against pathogen microbes of the vagina provides a stronger and longer immune response, then the infection.

Abstract: Non-absorbent articles containing an additive are disclosed. The non-absorbent articles include an effective amount of an inhibitory compound such as cerulenin, triclosan, or hexachloroprene, for example, to substantially inhibit the production of TSST-1 by Gram positive bacteria.

Abstract: A pre-fill vaginal applicator comprising a tubular barrel having an open end and a dispensing end provided with at least one dispensing opening formed therein. A selectively removable closure, such as a snap cap or threaded cap, closes the dispensing end of the barrel. A resilient piston is selectively slidably positioned in the barrel and has an outer surface which is in sealing contact with the inner surface of the barrel to define a medication reservoir between the piston and dispensing end of the barrel. An elongated plunger is adapted to be inserted into the open end of the barrel so that the inner end thereof may be detachably connected to the piston. After the plunger has been connected to the piston, inward movement of the plunger causes the piston to force medication from the medication reservoir outwardly through the dispensing opening. Outward movement of the plunger with respect to the piston causes the plunger to disconnect from the piston.

Abstract: A method and apparatus of fortifying a population of fertile age women with folic acid to reduce the incidence of neural tube birth defects involves placing folic acid either in powder, microcapsule, gel, cream, tablet, capsule or other form in or on a feminine hygiene product such as a tampon or a menstrual pad and making such products available to the population of women so that their normal use of the tampons or other feminine hygiene products will result in absorption of a sufficient amount of folic acid to satisfy RDA requirements for women who may or have become pregnant. In certain embodiments, vitamin B12 and/or other nutrients or ingredients are added to the folic acid vehicle.

Abstract: An absorbent article has an absorbent material and an outer surface including an inhibitor which is partially bound to the absorbent material and substantially inhibits the colonization of bacteria within the absorbent article. An absorbent article has an absorbent material. The absorbent material has an outer surface. The absorbent article includes a pre-toxin limiting agent which is partially bound to the absorbent material and substantially retards the production of bacteria-produced toxins by the bacteria residing within the absorbent article. An absorbent article has an absorbent material. The absorbent material has an outer surface. The absorbent article includes a toxin enclosing agent. The toxin enclosing agent substantially inhibits the migration of toxin outwardly from within the absorbent article towards the outer surface of the absorbent article.

Abstract: A method of treating menorrhagia and/or dysmenorrhoea in a patient the method comprising administering to the patient an antagonist of a prostaglandin EP2 and/or EP4 receptor. Preferably the patient is a human female.